International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
← catalyst calendarNCT05669989 · readout in 833 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 2
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
70estimated
Sites
37
Countries
Australia, Brazil, Chile +14
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-04-05 | actual | When the study began enrolling |
| Primary completion | 2028-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2023-01-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Plasma Cell Myeloma
Interventions
- Drug: Isatuximab intravenous (IV) — also filed as SARCLISA®, SAR650984
- Drug: Cemiplimab (SAR439684)
- Drug: Dexamethasone
- Drug: Lenalidomide
- Drug: Pomalidomide
- Drug: Isatuximab subcutaneous (SC) — also filed as SARCLISA®, SAR650984
- Drug: Carfilzomib
Primary outcome
what the primary-completion date above is the date OFNumber of participants with treatment-emergent adverse events
measured Baseline to 42 months
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed